Trials / Completed
CompletedNCT00651703
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients
Safety, Tolerability, and Immunogenicity of CYT004-MelQbG10 Vaccine With or Without Immunostimulating Adjuvant in HLA-A2 Positive Patients With Stage III/IV Malignant Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Cytos Biotechnology AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate a specific cellular immune response in melanoma patients that have been vaccinated with a Melan-A VLP vaccine alone or in combination with different adjuvants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CYT004-MelQbG10 + Montanide | |
| BIOLOGICAL | CYT004-MelQbG10 + Montanide + Imiquimod | |
| BIOLOGICAL | CYT004-MelQbG10 + Imiquimod | |
| BIOLOGICAL | CYT004-MelQbG10 intra nodal injection |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2009-12-01
- Completion
- 2010-07-01
- First posted
- 2008-04-03
- Last updated
- 2010-11-15
Locations
2 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00651703. Inclusion in this directory is not an endorsement.